Jamila K Stockman1, Jennifer L Syvertsen2, Angela M Robertson3, Natasha T Ludwig-Barron4, Julie N Bergmann4, Lawrence A Palinkas5. 1. Division of Global Public Health, Department of Medicine, School of Medicine, University of California, San Diego, La Jolla, California. Electronic address: stockman78@hotmail.com. 2. Department of Anthropology, College of Arts and Sciences, Ohio State University, Columbus, Ohio. 3. Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts; The Fenway Institute, Fenway Health, Boston, Massachusetts. 4. Division of Global Public Health, Department of Medicine, School of Medicine, University of California, San Diego, La Jolla, California. 5. School of Social Work, University of Southern California, Los Angeles, California.
Abstract
BACKGROUND: Female-initiated barrier methods for the prevention of HIV may be an effective alternative for drug-using women who are unable to negotiate safe sex, often as a result of physical and/or sexual partner violence. METHODS: Utilizing a SAVA (substance abuse, violence, and AIDS) syndemic framework, we qualitatively examined perspectives on female condoms and vaginal microbicides among 18 women with histories of methamphetamine abuse and partner violence in San Diego, California. FINDINGS: Most women were not interested in female condoms owing to perceived discomfort, difficulty of insertion, time-intensive effort, and unappealing appearance. Alternatively, most women viewed vaginal microbicides as a useful method. Positive aspects included convenience, ability to disguise as a lubricant, and a sense of control and empowerment. Concerns included possible side effects, timing of application, and unfavorable characteristics of the gel. Acceptability of female-initiated barrier methods was context dependent (i.e., partner type, level of drug use and violence that characterized the sexual relationship). CONCLUSIONS: Findings indicate that efforts are needed to address barriers identified for vaginal microbicides to increase its uptake in future HIV prevention trials and marketing of future Food and Drug Administration-approved products. Strategies should address gender-based inequalities (e.g., partner violence) experienced by drug-using women and promote female empowerment. Education on female-initiated barrier methods is also needed for women who use drugs, as well as health care providers and other professionals providing sexual health care and contraception to women with histories of drug use and partner violence.
BACKGROUND: Female-initiated barrier methods for the prevention of HIV may be an effective alternative for drug-using women who are unable to negotiate safe sex, often as a result of physical and/or sexual partner violence. METHODS: Utilizing a SAVA (substance abuse, violence, and AIDS) syndemic framework, we qualitatively examined perspectives on female condoms and vaginal microbicides among 18 women with histories of methamphetamine abuse and partner violence in San Diego, California. FINDINGS: Most women were not interested in female condoms owing to perceived discomfort, difficulty of insertion, time-intensive effort, and unappealing appearance. Alternatively, most women viewed vaginal microbicides as a useful method. Positive aspects included convenience, ability to disguise as a lubricant, and a sense of control and empowerment. Concerns included possible side effects, timing of application, and unfavorable characteristics of the gel. Acceptability of female-initiated barrier methods was context dependent (i.e., partner type, level of drug use and violence that characterized the sexual relationship). CONCLUSIONS: Findings indicate that efforts are needed to address barriers identified for vaginal microbicides to increase its uptake in future HIV prevention trials and marketing of future Food and Drug Administration-approved products. Strategies should address gender-based inequalities (e.g., partner violence) experienced by drug-using women and promote female empowerment. Education on female-initiated barrier methods is also needed for women who use drugs, as well as health care providers and other professionals providing sexual health care and contraception to women with histories of drug use and partner violence.
Authors: A van der Straten; E T Montgomery; H Cheng; L Wegner; G Masenga; C von Mollendorf; L Bekker; S Ganesh; K Young; J Romano; A Nel; C Woodsong Journal: AIDS Behav Date: 2012-10
Authors: Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor Journal: Science Date: 2010-07-19 Impact factor: 47.728
Authors: Judith B Cohen; Alice Dickow; Kathryn Horner; Joan E Zweben; Joseph Balabis; Denna Vandersloot; Chris Reiber Journal: Am J Addict Date: 2003 Oct-Dec
Authors: Marian Reiff; Christine Wade; Maria T Chao; Fredi Kronenberg; Linda F Cushman Journal: J Womens Health (Larchmt) Date: 2008-10 Impact factor: 2.681
Authors: Toral Zaveri; Cordelia A Running; Lahari Surapaneni; Gregory R Ziegler; John E Hayes Journal: Drug Deliv Transl Res Date: 2016-10 Impact factor: 4.617